ASH: Very first shot across the bow for CAR T cells in numerous myeloma Key clinical point: The very first clinical trial of a CAR targeting BCMA demonstrated strong antimyeloma activity in patients with at least three prior lines of myeloma therapy. Major finding: Myeloma in plasma cells was diminished from 90% to 0% in one patient.
Read More »ASH: Very first shot across the bow for CAR T cells in numerous myeloma, Hematology News
